9 registrations that name desmopressin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 9 registrations
Status
Phase
2US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 9 registrations
RecruitingNCT06635629
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
Phase 2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
About 140 people
Started Dec 12, 2024
In plain words A Phase 2 study of desmopressin in people 18 to 70, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It plans to enroll about 140 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70; healthy volunteers accepted. Conditions: Cushing Syndrome.
Aged 18-70 years
Agreement to adhere to Lifestyle Considerations throughout the study.
Evidence of acceptable laboratory testing results within four weeks of the first test day, as shown by medical record review:
Hematocrit at entry >=33 %
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Desmopressin; Dexamethasone
Registered summary
Background: Cushing syndrome (CS) is a set of diseases that develop when the body produces too much adrenocorticotropic hormone (ACTH). ACTH stimulates the production of a hormone called cortisol. Excess cortisol can cause serious issues, such as diabetes, high blood pressure, weight gain, and mood changes. Diagnosing CS early can be difficult. One test used to diagnose CS, the desmopressin (Desmo) stimulation test (DesmoST), has not been studied in enough people to know how accurate it is. Objective: To find ways to improve the DesmoST. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT04569591
DDAVP for Pituitary Adenoma
No phase
National Institute of Neurological Disorders and Stroke (NINDS)
About 22 people
Started Mar 9, 2026
In plain words A study of desmopressin in people 8 to 99, run by National Institute of Neurological Disorders and Stroke (NINDS). It plans to enroll about 22 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 8 to 99. Conditions: Cushing's Disease; Pituitary Adenoma.
Subjects aged 8 or older with biochemical evidence of Cushing s disease and a clinical MRI pituitary neuroradiology result of negative or possible adenoma (e.g. "no tumor" or "possible tumor")
MRI of the pituitary gland with and without contrast obtained within 9 months of screening
For newly diagnosed Cushing s disease cases, IPSS is required.
Ability to undergo PET-imaging without general anesthesia
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Desmopressin acetate
Registered summary
This study is designed as a single institution trial. The study utilizes safe and clinically-validated tools for preoperative workup of patients with small pituitary tumors. DDAVP stimulation and 18F-labeled fluoro-deoxyglucose (FDG) uptake for PET-imaging will be used to detect MRI-negative pituitary adenomas in patients with Cushing s disease. Patients who have MRI-negative pituitary microadenomas will undergo FDG PET-imaging with DDAVP stimulation. Intravenous FDG will be given approximately four hours following DDAVP administration. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT05467033
Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin
Phase 3
Medical University of Bialystok
About 424 people
Started Sep 1, 2022
In plain words A Phase 3 study of desmopressin in people 18 to 99, run by Medical University of Bialystok. It plans to enroll about 424 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 99. Conditions: Kidney Biopsy.
≥ 18 years old
Ability to provide Informed Consent
Qualification by nephrologist to kidney biopsy in accordance to current standards
Initial haemoglobin concentration > 8g/dl and PLT count >100 x103/μL
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Desmopressin; intravenous infusion NaCl
Registered summary
It is a randomized, multicenter, double-blind, placebo controlled, interventional clinical trial that will be conducted in Poland, in about 6 Hospital Nephrology Departments to evaluate the safety and effectiveness of desmopressin on the prevention of bleeding after percutaneous needle kidney biopsy in patients with rare and ultrarare glomerulonephritis.
Where, as registered
No US site; Poland (1).
RecruitingNCT06020495
Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia
Phase 3
Assistance Publique - Hôpitaux de Paris
About 260 people
Started Dec 17, 2024
In plain words A Phase 3 study of desmopressin in people 18 and older, run by Assistance Publique - Hôpitaux de Paris. It plans to enroll about 260 people at 12 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Hyponatremia.
Adults ( ≥18 years)
Current admission in ICU
Severe hyponatremia defined by SNa <120 mmol/L in the presence of neurological symptoms (seizures, stupor defined as Glasgow score < 12, or signs of brain herniation) or by SNa <115 mmol/L
Normal or decreased extracellular fluid volume
The exclusion criteria are on the listing.
What it tests, as registered
DDAVP; Standard hyponatremia treatment
Registered summary
ICU patients with severe hyponatremia and a high risk of rapid SNa overcorrection.
Where, as registered
No US site; France (12).
RecruitingNCT07776977
Bedtime Device Restriction and Desmopressin in PMNE.
No phase
Al-Azhar University
About 140 people
Started Aug 20, 2026
In plain words A study of desmopressin in people 6 to 14, run by Al-Azhar University. It plans to enroll about 140 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 6 to 14. Conditions: Primary Monosymptomatic Nocturnal Enuresis.
Age 6-14 years.
Diagnosis of PMNE (≥2 wet nights/week for ≥6 months, no daytime symptoms, no prior sustained dryness >6 months).
Willingness to take oral desmopressin nightly for 8 weeks.
Parent/guardian able to monitor and report screen time and wet nights.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Desmopressin; Bedtime digital-device restriction
Registered summary
This randomized controlled trial will evaluate whether restricting bedtime digital-device use improves the response to desmopressin in children with primary monosymptomatic nocturnal enuresis. Participants will receive desmopressin for 8 weeks and will be assigned to either bedtime device restriction or usual screen habits.
Where, as registered
No US site; Egypt (1).
RecruitingNCT07199894
Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE
Phase 3
Mansoura University
About 120 people
Started Dec 1, 2024
In plain words A Phase 3 study of desmopressin in people 6 to 18, run by Mansoura University. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 6 to 18. Conditions: Nocturnal Enuresis in Children.
The goal of this clinical trial is to compare combination of Solifenacin and MIrabegron in treatment of primary mono-symptomatic nocturnal enuresis in children. It will also learn about the safety of that combination. The main questions it aims to answer are: Does combination of Solifenacin and MIrabegron lower the number of wet nights? What medical problems do participants have when taking combination of Solifenacin and MIrabegron? Researchers will compare the combination to omegapress to see if the combination works better to treat primary mono-symptomatic nocturnal enuresis. The full summary is on the listing.
Where, as registered
No US site; Egypt (1).
RecruitingNCT06337838
Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
Phase 3
Hamilton Health Sciences Corporation
About 100 people
Started Jun 9, 2025
In plain words A Phase 3 study of desmopressin in people 18 and older, run by Hamilton Health Sciences Corporation. It plans to enroll about 100 people at 3 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Chronic Kidney Diseases; Acute Kidney Injury; Bleeding; Surgery.
One of either:
Planned noncardiac surgery (elective, urgent, or emergency surgery);
Expected to require at least an overnight hospital admission after surgery;
Age ≥18 years; and
1 more inclusion criterion and the exclusion criteria are on the listing.
The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.
Where, as registered
No US site; Canada (3).
RecruitingNCT07179991
DDAVP Effect by TEG6 in Cardiac Surgery
Observational
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
About 100 people
Started Aug 1, 2026
In plain words An observational study of desmopressin in people 18 and older, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Intraoperative Bleeding.
Age 18 years and above
Undergoing elective cardiac surgery with cardiopulmonary bypass
Able to provide informed consent
The exclusion criteria are on the listing.
What it tests, as registered
Desmopressin after protamine reversal
Registered summary
Cardiopulmonary bypass (CPB) is a process that uses a pump that temporarily takes over the function of the heart and lungs during cardiac surgery to maintain blood circulation and oxygenation. Using CPB during cardiac surgery can result in complications with blood clotting. Blood clotting is achieved when molecules in the blood, called platelets, are able to form together with the help of other clotting factors to form a clot. A drug called desmopressin (DDAVP) is used to help blood clot properly by increasing the amount of clotting factors in the blood. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
Not yet recruitingNCT07855315
FESS With or Without Intranasal Desmopressin in Chronic Rhinosinusitis With Nasal Polyps
No phase
Services Institute of Medical Sciences, Pakistan
About 174 people
Starts Oct 15, 2026 (estimated)
In plain words A study of desmopressin in people 18 to 60, run by Services Institute of Medical Sciences, Pakistan. It plans to enroll about 174 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Chronic Sinusitis; Nasal Polyposis.
Patients aged 18-60 years.
Diagnosed cases of chronic rhinosinusitis with bilateral nasal polyps.
Patients planned for elective Functional Endoscopic Sinus Surgery (FESS).
Patients with ASA physical status I or II.
The exclusion criteria are on the listing.
What it tests, as registered
Desmopressin Acetate Nasal, 10 μg/0.1 ml per spray; Functional Endoscopic Sinus Surgery
Registered summary
Chronic rhinosinusitis with nasal polyps is a condition that causes long-lasting inflammation and swelling in the nose and sinuses and may lead to nasal blockage, nasal discharge, facial pressure, and reduced sense of smell. Functional Endoscopic Sinus Surgery (FESS) is a surgical treatment used when medical treatment has not adequately controlled the condition. Bleeding during FESS can make it difficult for the surgeon to see and operate safely. The full summary is on the listing.